Biogen Pharmachem Industries (531752) Q4 24/25 earnings summary

Executive summary

• Audited financial results for the year ended March 31, 2025, were approved by the Board on May 23, 2025.

• Statutory auditors issued an unmodified opinion on the financial statements.

Financial highlights

• Revenue from operations for FY25 was Rs. 238.15 lakhs, up from Rs. 135.23 lakhs in FY24.

• Net profit after tax for FY25 stood at Rs. 193.07 lakhs, compared to a loss of Rs. 29.27 lakhs in FY24.

• Total comprehensive income for FY25 matched net profit at Rs. 193.07 lakhs.

• Earnings per share (EPS) for FY25 was Rs. 0.03, compared to Rs. (0.00) in FY24.

Key financial ratios and metrics

• Paid-up equity share capital remained at Rs. 6,526.03 lakhs.

• Other equity improved to Rs. 2,666.74 lakhs from Rs. (873.99) lakhs year-over-year.

• Total assets increased to Rs. 9,201.77 lakhs as of March 31, 2025, from Rs. 5,682.23 lakhs a year earlier.